Variability of oxidative stress biomarkers in hemodialysis patients

Biomarkers

Volumn 19, Issue 2, 2014, Pages 154-158

  Dahwa, Rumbidzai ^a   Fassett, Robert G ^b   Wang, Zaimin ^b   Briskey, David ^b   Mallard, Alistair R ^b   Coombes, Jeff S ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Coefficient of variation; Index of individuality; Kidney disease; Plasma isoprostanes; Protein carbonyls; Reference change value

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD PROTEINS; F2-ISOPROSTANES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84894573838     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.867533     Document Type: Article

References (18)

1. Block G, Dietrich M, Norkus E, et al. (2006). Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology 17:404-12.
2. Cappelli G, Lucchi L, Bonucchi D, et al. (1989). Polymorphonuclear oxygen free radical production and complement activation induced by dialysis membranes as assayed in an experimental model. Blood Purif 7:293-300.
3. Coombes JS, Fassett RG. (2012). Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int 81:233-46.
4. Dalle-Donne I, Rossi R, Giustarini D, et al. (2003). Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329:23-38.
5. Davies SS, Roberts II LJ. (2011). F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 50:559-66.
6. Fraser CG. (2012). Reference change values. Clin Chem Lab Med 50: 807-12.
7. Fraser CG, Harris EK. (1989). Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 27: 409-37.
8. Grace B, Hurst K, Mcdonald S. (2012). ANZDATA Registry 2012 Report. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry. Available from: http://www.anzdata.org.au/anzdata/AnzdataReport/ 33rdReport/Ch03.pdf [lastaccessed 29 Jul 2013].
9. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. (2002). The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-38.
10. Jones DP. (2006). Redefining oxidative stress. Antioxid Redox Signal 8: 1865-79.
11. Kadiiska MB, Gladen BC, Baird DD, et al. (2005). Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 38:698-710.
12. Levine RL, Garland D, Oliver CN, et al. (1990). Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464-78.
13. Morrow JD, Awad JA, Kato T, et al. (1992). Formation of novel noncyclooxygenase- derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 90:2502-7.
14. Mullins AL, Van Rosendal SP, Briskey DR, et al. (2013). Variability in oxidative stress biomarkers following a maximal exercise test. Biomarkers 18:446-54.
15. Petersen PH, Fraser CG, Sandberg S, Goldschmidt H. (1999). The index of individuality is often a misinterpreted quantity characteristic. Clin Chem Lab Med 37:655-61.
16. Roberts LJ, Morrow JD. (2000). Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28:505-13.
17. Stocker R, Keaney Jr JF. (2004). Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381-478.
18. Yu X, Ho CS, Lam CW. (2004). Biological variation of plasma F2-isoprostane-III and arachidonic acid in healthy individuals. Clin Chem 50:1428-30.